Using a symptom-specific instrument to measure patient-reported daily functioning in patients with cancer

被引:20
|
作者
Shi, Qiuling [1 ]
Mendoza, Tito R. [1 ]
Wang, Xin Shelley [1 ]
Cleeland, Charles S. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, 1515 Holcombe Blvd,Unit 1450, Houston, TX 77030 USA
关键词
Patient-reported outcomes; Daily functioning; Cancer; Symptom-specific instrument; QUALITY-OF-LIFE; CELL LUNG-CANCER; RESPONSIVENESS; OUTCOMES; SURGERY; BURDEN; BREAST; RECOVERY; VALIDITY; CRITERIA;
D O I
10.1016/j.ejca.2016.07.027
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Improving, stable, or deteriorating patient functioning is critical to assess in cancer care and in oncology clinical trials. We evaluated the performance of the six-item interference subscale of the MD Anderson Symptom Inventory (MDASI) compared with two commonly used patient-reported measures of functioning as a reference: the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) and the Medical Outcomes Study Short Form 12-item health survey (SF-12). Methods: In this secondary analysis of two databases, MDASI versus QLQ-C30 (431 multiple myeloma patients) and MDASI versus SF-12 in solid tumours (285 lung and 91 gastrointestinal cancer patients), we used Pearson correlations to test relationships of four SF-12 and five QLQ-C30 functioning subscales with MDASI total interference (MDASI-INTFER), physical (MDASI-WAW), and affective (MDASI-REM) subscales. We used area under the curve (AUC) to quantify ability to differentiate performance status levels, and Glass Delta effect size (ES) and standardised response mean to evaluate responsiveness to aggressive cancer treatment. Results: MDASI-WAW was strongly correlated with QLQ-C30 and SF-12 physical subscales across all three cancer types (all r >= 0.7, P < 0.0001). The MDASI-WAW displayed AUCs that were similar to the physical functioning scales of QLQ-C30 and SF-12 (>0.7). MDASI-WAW responsiveness was equivalent to the SF-12 physical functioning subscale for chemoradiotherapy (ES = 0.72 for MDASI-WAW; 0.55 for SF-12), surgery (ES = 0.92 for MDASI-WAW; 0.97 for SF-12), and worsening of general health (ES = 1.22 for MDASI-WAW; 1.05 for SF-12). Conclusions: MDASI interference is a valid measure of symptom-related functional impairment. The three-item MDASI-WAW subscale is comparable to the SF-12 in responsiveness to functional deterioration during aggressive cancer treatment. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:83 / 90
页数:8
相关论文
共 50 条
  • [21] Validation of the psoriasis symptom inventory (PSI), a patient-reported outcome measure
    Martin, Mona L.
    Bushnell, Donald M.
    Gordon, Kenneth
    Huang, Xingyue
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB207 - AB207
  • [22] Development and content validity of a hemodialysis symptom patient-reported outcome measure
    Jennifer E. Flythe
    Adeline Dorough
    Julia H. Narendra
    Rebecca L. Wingard
    Lorien S. Dalrymple
    Darren A. DeWalt
    Quality of Life Research, 2019, 28 : 253 - 265
  • [23] Replenishing a computerized adaptive test of patient-reported daily activity functioning
    Haley, Stephen M.
    Ni, Pengsheng
    Jette, Alan M.
    Tao, Wei
    Moed, Richard
    Meyers, Doug
    Ludlow, Larry H.
    QUALITY OF LIFE RESEARCH, 2009, 18 (04) : 461 - 471
  • [24] Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer
    Advani, Shailesh M.
    Shi, Quilling
    Overman, Michael J.
    Loree, Jonathan M.
    Lam, Michael
    Morris, Van
    Shureiqi, Imad
    Kee, Bryan
    Dasari, Arvind
    Vilar, Eduardo
    Sarshekeh, Amir Mehrvarz
    Lin, Huei K.
    Manue, Shanequa
    Hamilton, Stan
    Raghav, Kanwal
    Maru, Dipen
    Kopetz, Scott
    Wang, Xin Shelley
    CLINICAL COLORECTAL CANCER, 2020, 19 (01) : 48 - +
  • [25] Patient-reported care satisfaction and symptom burden in hospitalized patients with cancer.
    Kaslow-Zieve, Emilia R.
    Qian, Carolyn L.
    Azoba, Chinenye C.
    Wang, Irene
    Van Seventer, Emily E.
    Newcomb, Richard
    Jackson, Vicki A.
    Ryan, David P.
    Greer, Joseph A.
    El-Jawahri, Areej
    Temel, Jennifer S.
    Nipp, Ryan David
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Development of the Anemia Impact Measure (AIM): A Disease-Specific Patient Reported outcome (PRO) Instrument to Measure Anemia Symptoms and Their Impact on Functioning in Cancer Patients Receiving Chemotherapy
    Kleinman, Leah
    Benjamin, Katy
    Viswanathan, Hema
    Mattera, Maria Stoeckl
    Bosserman, Linda D.
    Blayney, Douglas W.
    Revicki, Dennis
    BLOOD, 2008, 112 (11) : 250 - 250
  • [27] Measurement of Symptoms Using Patient-Reported Symptom Assessment Scale in Children with Cancer
    Goh, X. N.
    Chang, G. C. Y.
    Chan, A.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S507 - S508
  • [28] Capturing the Patient's Experience: Using Qualitative Methods to Develop a Measure of Patient-Reported Symptom Burden: An Example From Ovarian Cancer
    Williams, Loretta A.
    Agarwal, Sonika
    Bodurka, Diane C.
    Saleeba, Angele K.
    Sun, Charlotte C.
    Cleeland, Charles S.
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2013, 46 (06) : 837 - 845
  • [29] Using patient-reported outcomes (PROs) for symptom monitoring
    Lai-Kwon, Julia
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 : 106 - 106
  • [30] Patient-reported symptom burden and functioning in patients with advanced esophageal, gastroesophageal junction (GEJ), and gastric cancer undergoing chemotherapy.
    Wang, Xin Shelley
    Hess, Lisa M.
    Lin Fang-Yu
    Chen, Tsun Hsuan
    Gonzalez, Elizabeth
    Garcia-Gonzalez, Araceli
    Chatterjee, Anindya
    Liepa, Astra M.
    Williams, Loretta A.
    Cleeland, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)